MedImmune, Compugen sign immuno-oncology deal

This article was originally published here

Compugen has signed an exclusive license agreement with AstraZeneca’s subsidiary MedImmune for the development of bi-specific and multi-specific immuno-oncology antibody products.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply